Search

Your search keyword '"Cafro, A M"' showing total 13 results
Start Over Author "Cafro, A M"
13 results on '"Cafro, A M"'

1. P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL

Author

Larocca, A., primary, D’Agostino, M., additional, Giuliani, N., additional, Antonioli, E., additional, Zambello, R., additional, Ronconi, S., additional, Vincelli, I. D., additional, Ciceri, F., additional, Falcone, A. P., additional, Michieli, M., additional, Cattel, F., additional, Capra, A., additional, Grasso, M., additional, Cafro, A. M., additional, Bonello, F., additional, Floris, R., additional, Offidani, M., additional, Sciorsi, E., additional, Pietrantuono, G., additional, Curci, P., additional, Patriarca, F., additional, Cavo, M., additional, Mangiacavalli, S., additional, Benevolo, G., additional, Evangelista, A., additional, Ciccone, G., additional, Boccadoro, M., additional, Bruno, B., additional, and Bringhen, S., additional

Published
2023
Full Text
View/download PDF

2. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Author

Gay, F, Oliva, S, Petrucci, M T, Montefusco, V, Conticello, C, Musto, P, Catalano, L, Evangelista, A, Spada, S, Campbell, P, Ria, R, Salvini, M, Offidani, M, Carella, A M, Omedé, P, Liberati, A M, Troia, R, Cafro, A M, Malfitano, A, Falcone, A P, Caravita, T, Patriarca, F, Nagler, A, Spencer, A, Hajek, R, Palumbo, A, and Boccadoro, M

Published
2017
Full Text
View/download PDF

4. P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA

Author

Raab, M. S., primary, Cohen, Y. C., additional, Schjesvold, F., additional, Aardalen, K., additional, Oka, A., additional, Spencer, A., additional, Wermke, M., additional, Hari, P., additional, Kaufman, J. L., additional, Cafro, A. M., additional, Ocio, E. M., additional, Doki, N., additional, Henson, K., additional, Trabucco, G., additional, Juif, P.-E., additional, Chawla, R., additional, Cotton, J., additional, Fessehatsion, A., additional, Fan, L., additional, Blankenship, J., additional, Granda, B., additional, Lu, H., additional, and De Vita, S., additional

Published
2022
Full Text
View/download PDF

9. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

Author

Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omede, P., Ronconi, S., Cangialosi, C., Podda, L., Palmas, A., Malfitano, A., Rivoli, G., Belotti, A., Ciambelli, F., Vincelli, I. D., Cafro, A. M., Innao, V., Palumbo, A., Sonneveld, P., Spencer, A., Hajek, R., Boccadoro, M., Gay, F., and Hematology

Subjects
Cancer Research, medicine.medical_specialty, lenalidomide, Newly diagnosed, Neutropenia, lcsh:RC254-282, Gastroenterology, Article, maintenance, 03 medical and health sciences, 0302 clinical medicine, Prednisone, Internal medicine, Medicine, In patient, Multiple myeloma, Lenalidomide, Lenalidomide, Maintenance, Multiple myeloma, Newly diagnosed, Prednisone, business.industry, Maintenance, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, multiple myeloma, Pooled analysis, Oncology, 030220 oncology & carcinogenesis, Toxicity, prednisone, newly diagnosed, business, 030215 immunology, medicine.drug
Abstract

We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were progression-free survival, progression-free survival 2 and overall survival with both regimens. A secondary aim was to evaluate the impact of duration of maintenance on overall survival and on outcome after relapse. A total of 625 patients (lenalidomide-prednisone arm, n = 315, lenalidomide arm, n = 310) were analyzed. The median follow-up was 58 months. Median progression-free survival (25 vs. 19 months, p = 0.08), progression-free survival 2 (56 vs. 49 months, p = 0.9) and overall survival (73 months vs. NR, p = 0.08) were not significantly different between the two arms. Toxicity profiles of lenalidomide-prednisone and lenalidomide were similar, with the exception of neutropenia that was higher in the lenalidomide arm (grade &ge, 3: 9% vs. 19%, p &lt, 0.001), without an increase in the rate of infections. Overall survival (median NR vs. 49 months, p &lt, 0.001), progression-free survival from relapse (median 35 vs. 24 months, p = 0.004) and overall survival from relapse (median not reached vs. 41 months, p = 0.002) were significantly longer in patients continuing maintenance for &ge, 2 years. We showed that the addition of prednisone at 25 or 50 mg every other day (eod) to lenalidomide maintenance did not induce any significant advantage.

Published
2019
Full Text
View/download PDF

10. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Author

Ludwig, H, primary, Weisel, K, additional, Petrucci, M T, additional, Leleu, X, additional, Cafro, A M, additional, Garderet, L, additional, Leitgeb, C, additional, Foa, R, additional, Greil, R, additional, Yakoub-Agha, I, additional, Zboralski, D, additional, Vauléon, S, additional, Dümmler, T, additional, Beyer, D, additional, Kruschinski, A, additional, Riecke, K, additional, Baumann, M, additional, and Engelhardt, M, additional

Published
2017
Full Text
View/download PDF

11. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Author

Gay, F, primary, Oliva, S, additional, Petrucci, M T, additional, Montefusco, V, additional, Conticello, C, additional, Musto, P, additional, Catalano, L, additional, Evangelista, A, additional, Spada, S, additional, Campbell, P, additional, Ria, R, additional, Salvini, M, additional, Offidani, M, additional, Carella, A M, additional, Omedé, P, additional, Liberati, A M, additional, Troia, R, additional, Cafro, A M, additional, Malfitano, A, additional, Falcone, A P, additional, Caravita, T, additional, Patriarca, F, additional, Nagler, A, additional, Spencer, A, additional, Hajek, R, additional, Palumbo, A, additional, and Boccadoro, M, additional

Published
2016
Full Text
View/download PDF

13. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H

Author

Montillo, M, primary, Tedeschi, A, additional, Rossi, V, additional, Cairoli, R, additional, Pungolino, E, additional, Intropido, L, additional, Cafro, A M, additional, D'Avanzo, G, additional, Farioli, R, additional, Brando, B, additional, Scarpati, B, additional, Veronese, S, additional, and Morra, E, additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results